ReviewAlcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism2008
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Review in Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 19 citations in OpenAlex.
- Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants.Frontiers in psychiatry · 2021Article
- Alcohol Intoxication and Cognition: Implications on Mechanisms and Therapeutic Strategies.Frontiers in neuroscience · 2020Review
- Epigenetic regulation of motivated behaviors by histone deacetylase inhibitors.Neuroscience and biobehavioral reviews · 2019Review
- FMRP regulates an ethanol-dependent shift in GABANature communications · 2016Article
- Anti-Alcohol and Anxiolytic Properties of a New Chemical Entity, GET73.Frontiers in psychiatry · 2012Article
- Medications for unhealthy alcohol use: across the spectrum.Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Developing pharmacotherapies to treat alcohol dependence and associated health problems traditionally has been based on gaining a better understanding of the neuroscience underlying alcohol-drinking behavior. To date, three medications have been approved for the treatment of alcohol dependence: disulfiram (Antabuse®), naltrexone (Revia®, Vivitrol®, and Naltrel®), and acamprosate (Campral®). However, these medications have modest efficacy, and there is a great need for newer medications that target different neurochemical systems and which could be used either as adjunctive treatments or to treat subpopulations of drinkers. Furthermore, it also is important to improve current treatment options by understanding and incorporating differences in how people with certain genes respond to medication (i.e., pharmacogenetic differences).
Indexed as
Identifiers
23584013PMC3860468W1583803662What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.